BUSINESS

• Kyowa Kirin to Boost Overseas Biz in Next 5 Years, Japan Market Unpredictable: President
  February 2, 2016

• Astellas, Tohoku Univ. Spinoff Link Up on Gene Therapy for Retinitis Pigmentosa
  February 2, 2016

• Sanofi Files Japan NDA for Plerixafor in Response to Govt Request
  February 2, 2016

• Retooling Generic Business - 3: Eisai “Carefully Considering” Future Course; “Not a Core Field,” Mitsubishi Tanabe Says
  February 2, 2016

• Daiichi Sankyo to Continue Negotiations with FDA on Edoxaban Restriction: CEO
  February 1, 2016

• Kyowa Kirin Enjoys 87% Profit Jump in 2015
  February 1, 2016

• Kyowa Kirin to Forge Stand-Alone Sales Regime in US: 5 Year Plan
  February 1, 2016

• Retooling Generic Business - 2: Mochida Seeks to Expand Alliances for Biosimilar Candidates
  February 1, 2016

• FDA OKs Eisai’s Halaven for Liposarcoma
  February 1, 2016

• Chugai Positions Mid-Sized Molecule Drugs as Third Pillar of Business, Aims to Produce First Candidate within 3 Years
  February 1, 2016

• Chugai Foresees Tepid Growth for Next 3 Years: New Biz Plan
  January 29, 2016

• Kadcyla Development for Gastric Cancer Discontinued: Chugai
  January 29, 2016

• Chugai Delivers Record Earnings, but Pegasys Falters on IFN-Free Hep C Therapies
  January 29, 2016

• Shionogi, Nissan Chemical Ink Collaboration Pact on Antifungals
  January 29, 2016

• Sumitomo Dainippon to Revise 5-Year Business Plan
  January 29, 2016

• Ferring Empowers Japan Unit, Local Head Mark Noggle Doubles as CEO
  January 29, 2016

• Retooling Generic Business - 1: Daiichi Sankyo Espha Shifting Its Focus to AGs
  January 29, 2016

• Shionogi Files Japan NDA for ADHD Drug Licensed from Shire
  January 28, 2016

• Mochida Seeks Adenomyosis Indication for Dinagest
  January 28, 2016

• 140 Hep C Patients Receive Viekirax in 1st Month
  January 27, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 494
• 495
• 496
• 497
• 498
• 499
• 500
• 501
• 502
• …
• Next ›
• 最終 »